Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Cancer Immunology, Immunotherapy : CII
|
December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
Alberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
Mayer N Fishman, Christopher R Garrett, George R Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
George R Simon, Claire F Verschraegen, Pasi A Jänne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
Jade Homsi, George R Simon, Chris R Garrett, et al.
The Oncologist
|
July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Carl M Gay, Yanhong Zhou, J Jack Lee, et al.
Investigational New Drugs
|
September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
Jhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
Cancer Chemotherapy and Pharmacology
|
March 25, 2011
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
George R Simon, Robert L Ilaria, Mika A Sovak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma
Carmen Behrens, Luisa M Solis, Heather Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
George R Simon, Christopher R Garrett, Stephen C Olson, et al.
Cold Spring Harbor Molecular Case Studies
|
January 5, 2017
ALK: a tyrosine kinase target for cancer therapy
Vijaykumar R Holla, Yasir Y Elamin, Ann Marie Bailey, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Cancer Immunology, Immunotherapy : CII
|
December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
Alberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
Mayer N Fishman, Christopher R Garrett, George R Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
George R Simon, Claire F Verschraegen, Pasi A Jänne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
Jade Homsi, George R Simon, Chris R Garrett, et al.
The Oncologist
|
July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Carl M Gay, Yanhong Zhou, J Jack Lee, et al.
Investigational New Drugs
|
September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
Jhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
Cancer Chemotherapy and Pharmacology
|
March 25, 2011
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
George R Simon, Robert L Ilaria, Mika A Sovak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma
Carmen Behrens, Luisa M Solis, Heather Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2006
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
George R Simon, Christopher R Garrett, Stephen C Olson, et al.
Cold Spring Harbor Molecular Case Studies
|
January 5, 2017
ALK: a tyrosine kinase target for cancer therapy
Vijaykumar R Holla, Yasir Y Elamin, Ann Marie Bailey, et al.
Page
of 8